Last reviewed · How we verify
zetomipzomib in open-label extension
At a glance
| Generic name | zetomipzomib in open-label extension |
|---|---|
| Also known as | KZR-616 |
| Sponsor | Kezar Life Sciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) (PHASE2)
- Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zetomipzomib in open-label extension CI brief — competitive landscape report
- zetomipzomib in open-label extension updates RSS · CI watch RSS
- Kezar Life Sciences, Inc. portfolio CI